Kolexia
Benbrahim Omar Hématologie
Benbrahim Omar
Hématologie
Centre Hospitalier Régional D'Orléans Hôpital de La Source
Orléans, France
102 Activités
24 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Déficits immunitaires Tumeurs hématologiques Myélome multiple Leucémie lymphoïde Leucémie myéloïde Leucémie chronique lymphocytaire à cellules B Lymphomes Tumeurs à plasmocytes

Collaborateurs

Voir plus
Arar Ali
Arar Ali
Centre Hospitalier Régional D'Orléans Hôpital de La Source, Orléans, France
Arakelyan-Laboure Nina
Arakelyan-Laboure Nina
Centre Hospitalier Régional D'Orléans Hôpital de La Source, Orléans, France
Jdid Ibrahim
Jdid Ibrahim
Centre Hospitalier Régional D'Orléans Hôpital de La Source, Orléans, France
Ochmann Marlene
Ochmann Marlene
Centre Hospitalier Régional D'Orléans Hôpital de La Source, Orléans, France

Industries

Voir plus
A+A
208 collaboration(s)
Dernière en 2023
IQVIA
166 collaboration(s)
Dernière en 2023
B3TSI
131 collaboration(s)
Dernière en 2023
Schlesinger Group France
27 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
EJHaem   13 décembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency: A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)
Essai Clinique (Takeda Pharmaceutical)   31 octobre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   18 avril 2023
FLIRT: A Randomized Phase III Trial Evaluating Two Strategies of Rituximab Administration for the Treatment of First Line/Low Tumor Burden Follicular Lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
Essai Clinique (Roche)   09 janvier 2023
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
Annual Meeting Abstracts 2022   15 novembre 2022
Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
Annual Meeting Abstracts 2022   15 novembre 2022
Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study
Annual Meeting Abstracts 2022   15 novembre 2022
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022